AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9695216 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide pulses
Number of subjects: 31
Study 9846242 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity profiles of adults with mild and moderate learning disabilities
Number of subjects: 24
Study 9846242 — intervention group
Group type: COMPARATOR
Intervention: Comparison with the general population
Number of subjects: 24
Study 9846242 — intervention group
Group type: COMPARATOR
Intervention: Department of Health recommendations for physical activity
Number of subjects: 24
Study 1864449 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% indomethacin spray
Number of subjects: 30
Study 1864449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 6347110 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized 0.5% fenoterol
Number of subjects: 40
Study 6347110 — intervention group
Group type: COMPARATOR
Intervention: Nebulized 1% isoetharine hydrochloride
Number of subjects: 40
Study 31343103 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable loop recorder (ILR) - 'Reveal XT', monitoring duration up to 3 months
Number of subjects: 32
Study 31343103 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive ambulatory ECG monitoring (NIAM) - 'Spyder' device, monitoring duration up to 14 days
Number of subjects: 32
Study 31342534 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron
Number of subjects: 125
Study 28292641 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide (LAN) 120mg every 28 days until disease progression or unacceptable toxicity
Number of subjects: 222
Study 28292641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 222
Study 28292641 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide (LAN)
Number of subjects: 222
Study 26915677 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib (100 mg twice daily)
Number of subjects: 41
Study 26915677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 24994555 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 279
Study 24994555 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 279
Study 23232637 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sphincterotomy (ES)
Number of subjects: 82
Study 23232637 — intervention group
Group type: COMPARATOR
Intervention: No endoscopic sphincterotomy (non-ES)
Number of subjects: 82
Study 19716238 — intervention group
Group type: EXPERIMENTAL
Intervention: EG 2: 70-85% HR max, n=20
Number of subjects: 60
Study 19716238 — intervention group
Group type: EXPERIMENTAL
Intervention: EG 1: 50-65% HR max, n=18
Number of subjects: 60
Study 19716238 — intervention group
Group type: COMPARATOR
Intervention: CG: no intervention, n=21
Number of subjects: 60
Study 17398147 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonmedicated PD patients
Number of subjects: 0
Study 17398147 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicated PD patients
Number of subjects: 0
Study 17398147 — intervention group
Group type: COMPARATOR
Intervention: Healthy elderly controls
Number of subjects: 0
Study 15863638 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure treatment
Number of subjects: 36
Study 15863638 — intervention group
Group type: COMPARATOR
Intervention: CD8+ T-lymphocytes of OSA patients
Number of subjects: 36
Study 12038931 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading on paper in their mother tongue
Number of subjects: 114
Study 12038931 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading on screen in their mother tongue
Number of subjects: 114
Study 12038931 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading on paper in English
Number of subjects: 114
Study 12038931 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading on screen in English
Number of subjects: 114
Study 12038931 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading in their mother tongue (combined paper and screen)
Number of subjects: 114
Study 12038931 — intervention group
Group type: COMPARATOR
Intervention: Reading on paper vs screen
Number of subjects: 114
Study 9296408 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (30 microg/kg)
Number of subjects: 60
Study 8362947 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm birth prevention program (intervention group)
Number of subjects: 2395
Study 8362947 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2395
Study 30156211 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular multimodal drug injection (200 mg ropivacaine, 30 mg ketorolac tromethamine, 0.3 mg epinephrine, 5 mg hexadecadrol)
Number of subjects: 110
Study 30156211 — intervention group
Group type: EXPERIMENTAL
Intervention: Periarticular multimodal drug injection
Number of subjects: 110
Study 30156211 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 110
Study 26857465 — intervention group
Group type: COMPARATOR
Intervention: Unassisted TPB
Number of subjects: 13
Study 26857465 — intervention group
Group type: EXPERIMENTAL
Intervention: Effortful swallow
Number of subjects: 13
Study 26857465 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger-resisted TPB
Number of subjects: 13
Study 26857465 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-resisted TPB
Number of subjects: 13
Study 26857465 — intervention group
Group type: COMPARATOR
Intervention: Saliva swallow
Number of subjects: 13
Study 26857465 — intervention group
Group type: COMPARATOR
Intervention: 15 mL water swallow
Number of subjects: 13
Study 25381136 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin (1.4 mg/m2 on days 1 and 8 every 21 days)
Number of subjects: 1864
Study 25381136 — intervention group
Group type: COMPARATOR
Intervention: Control (treatment of physician’s choice or capecitabine 1.25 g/m2 b.i.d. on days 1–14 every 21 days)
Number of subjects: 1864
Study 25381136 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 1864
Study 21769734 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity endurance training (4 days a week for 12 weeks at 75-80% maximum oxygen consumption for 45 min)
Number of subjects: 16
Study 21769734 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity endurance training
Number of subjects: 16
Study 21769734 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 16
Study 20571291 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 0
Study 18322990 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculin skin test (TST) with 10 mm cutoff
Number of subjects: 61
Study 18322990 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculin skin test (TST) with 5 mm cutoff
Number of subjects: 61
Study 18322990 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-step TST
Number of subjects: 61
Study 18322990 — intervention group
Group type: EXPERIMENTAL
Intervention: QuantiFeron test (QIFN)
Number of subjects: 61
Study 15964114 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic dynamometer assessment at various velocities (10 to 300 degrees/s)
Number of subjects: 27
Study 15964114 — intervention group
Group type: EXPERIMENTAL
Intervention: Normalized passive resistance measurement
Number of subjects: 27
Study 15964114 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflex responses elicitation
Number of subjects: 27
Study 14657750 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpedicular microscopic discectomy and transverse process resection (Group C)
Number of subjects: 12
Study 14657750 — intervention group
Group type: COMPARATOR
Intervention: Transverse process resection (Group B)
Number of subjects: 12
Study 14657750 — intervention group
Group type: COMPARATOR
Intervention: No release (Group A)
Number of subjects: 12
Study 10228288 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course indomethacin (0.2 to 0.1 to 0.1 mg/kg in 24 hours, n = 31)
Number of subjects: 61
Study 10228288 — intervention group
Group type: COMPARATOR
Intervention: Long course indomethacin (0.1 mg/kg every 24 hours for 7 times, n = 30)
Number of subjects: 61
Study 10228288 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course indomethacin
Number of subjects: 61
Study 10228288 — intervention group
Group type: COMPARATOR
Intervention: Long course indomethacin
Number of subjects: 61
Study 10228288 — intervention group
Group type: EXPERIMENTAL
Intervention: Short course indomethacin and Long course indomethacin
Number of subjects: 61
Study 8730606 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 ml of red wine (providing 30 g/day of alcohol)
Number of subjects: 11
Study 8730606 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g/day of alcohol diluted in 320 ml of clear fruit juice
Number of subjects: 11
Study 8730606 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 ml of dealcoholised red wine
Number of subjects: 11
Study 8730606 — intervention group
Group type: COMPARATOR
Intervention: Abstinence
Number of subjects: 11
Study 1321893 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy and radiotherapy (RT) including cisplatin 100 mg/m2 on days 1 and 29, vinblastine 3 mg/m2 on days 1, 3, 29, and 31, fluorouracil (5-FU) 30 mg/kg/d by infusion on days 1 to 3 and 29 to 31, and RT of 3,000 cGy in 15 fractions.
Number of subjects: 41
Study 1321893 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection following neoadjuvant treatment.
Number of subjects: 41
Study 1321893 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy and RT followed by additional chemotherapy and RT after surgery.
Number of subjects: 41
Study 6463794 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimization procedure
Number of subjects: 41
Study 6463794 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study 30591354 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone
Number of subjects: 202
Study 30591354 — intervention group
Group type: COMPARATOR
Intervention: Enzalutamide
Number of subjects: 202
Study 29884069 — intervention group
Group type: EXPERIMENTAL
Intervention: DIAL intervention
Number of subjects: 63
Study 29884069 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 63
Study 27157959 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational music
Number of subjects: 37
Study 27157959 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation music
Number of subjects: 37
Study 27157959 — intervention group
Group type: COMPARATOR
Intervention: No music
Number of subjects: 37
Study 24766759 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 307
Study 24766759 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation challenges
Number of subjects: 307
Study 21685369 — intervention group
Group type: EXPERIMENTAL
Intervention: Multistimulant home-based program, 10 home visits once per week.
Number of subjects: 96
Study 21685369 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified).
Number of subjects: 96
Study 21038652 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with blood glucose (BG) and blood pressure (BP) controlling (Group A)
Number of subjects: 130
Study 21038652 — intervention group
Group type: COMPARATOR
Intervention: Control group with BG, BP and blood lipid (BL) controlling (Group B)
Number of subjects: 130
Study 21038652 — intervention group
Group type: COMPARATOR
Intervention: Control group with BG, BP, BL controlling and vitamin E administration (Group C)
Number of subjects: 130
Study 21038652 — intervention group
Group type: EXPERIMENTAL
Intervention: Group with BG, BP, BL controlling and DSP administration (Group D)
Number of subjects: 130
Study 17992056 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle strengthening exercises using a Thera Band
Number of subjects: 32
Study 17992056 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture therapy and physical therapy
Number of subjects: 32
Study 15650967 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard laparoscopy
Number of subjects: 425
Study 15650967 — intervention group
Group type: EXPERIMENTAL
Intervention: Histology
Number of subjects: 425
Study 15650967 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-laparoscopy
Number of subjects: 425
Study 11930982 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 0
Study 11930982 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 9649928 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen
Number of subjects: 934
Study 9649928 — intervention group
Group type: COMPARATOR
Intervention: Aspirin and dipyridamole
Number of subjects: 934
Study 8547556 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Number of subjects: 100
Study 8547556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 2295911 — intervention group
Group type: EXPERIMENTAL
Intervention: Testicular biopsy
Number of subjects: 494
Study 2295911 — intervention group
Group type: EXPERIMENTAL
Intervention: Occult testicular leukemia (TL)
Number of subjects: 494
Study 2295911 — intervention group
Group type: COMPARATOR
Intervention: No biopsy
Number of subjects: 494
Study 799986 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofranil 25 mg three times daily
Number of subjects: 0
Study 799986 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study 30284349 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide (up to 14 mg)
Number of subjects: 3183
Study 30284349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3183
Study 28521380 — intervention group
Group type: EXPERIMENTAL
Intervention: PAT student tutor
Number of subjects: 94
Study 28521380 — intervention group
Group type: COMPARATOR
Intervention: University professor
Number of subjects: 94
Study 28521380 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall evaluation
Number of subjects: 94
Study 28521380 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrater reliability
Number of subjects: 94
Study 28521380 — intervention group
Group type: EXPERIMENTAL
Intervention: Point difference
Number of subjects: 94
Study 26113111 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidized zirconium femoral head with UHMWPE
Number of subjects: 100
Study 26113111 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel femoral head with UHMWPE
Number of subjects: 100
Study 26113111 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidized zirconium femoral head with HXLPE
Number of subjects: 100
Study 26113111 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel femoral head with HXLPE
Number of subjects: 100
Study 26113111 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Oxidized zirconium and Stainless steel)
Number of subjects: 100
Study 22492785 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention on low-sodium diet
Number of subjects: 52
Study 22492785 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no dietary instructions)
Number of subjects: 52
Study 20684664 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEP/heparin plaster
Number of subjects: 185
Study 20684664 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEP plaster
Number of subjects: 185
Study 20684664 — intervention group
Group type: COMPARATOR
Intervention: Placebo plaster
Number of subjects: 185
Study 18463399 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management intervention group (n = 344)
Number of subjects: 683
Study 18463399 — intervention group
Group type: COMPARATOR
Intervention: Case management control group (n = 339)
Number of subjects: 683
Study 18463399 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 683
Study 18463399 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with chronic bronchitis
Number of subjects: 683
Study 18463399 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with a relative with cancer
Number of subjects: 683
Study 15941146 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (1.25 to 5 mg per day)
Number of subjects: 40
Study 15941146 — intervention group
Group type: EXPERIMENTAL
Intervention: Betalok ZOK (12.5 to 100 mg per day)
Number of subjects: 40
Study 12817904 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg lithium
Number of subjects: 23
Study 12817904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 12817904 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion
Number of subjects: 23
Study 10423106 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme (ACE) inhibitors
Number of subjects: 0
Study 8947069 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (1,000 microg)
Number of subjects: 33
Study 8947069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 2017225 — intervention group
Group type: EXPERIMENTAL
Intervention: Antilymphocyte globulin, methylprednisolone, and cyclosporine
Number of subjects: 84
Study 2017225 — intervention group
Group type: COMPARATOR
Intervention: Antilymphocyte globulin and methylprednisolone
Number of subjects: 84
Study 6812750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 10 mg intravenously
Number of subjects: 9
Study 6812750 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 9 g/l)
Number of subjects: 9
Study 30118528 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform-switching implant (PS)
Number of subjects: 56
Study 30118528 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform-switching implant and bone graft (BG/PS)
Number of subjects: 56
Study 30118528 — intervention group
Group type: COMPARATOR
Intervention: Non-platform-switching implant (Non-PS)
Number of subjects: 56
Study 30118528 — intervention group
Group type: COMPARATOR
Intervention: Non-platform-switching implant and bone graft (BG/Non-PS)
Number of subjects: 56
Study 30118528 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform-switching implant (PS) and bone graft (BG/PS)
Number of subjects: 56
Study 27614801 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/d omega-3 fatty acid supplementation
Number of subjects: 20
Study 27614801 — intervention group
Group type: COMPARATOR
Intervention: Control (no omega-3 fatty acid supplementation)
Number of subjects: 20
Study 24930475 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary intra‐ocular lens (IOL) implantation
Number of subjects: 60
Study 24930475 — intervention group
Group type: COMPARATOR
Intervention: Press‐on spherical lens
Number of subjects: 60
Study 23162960 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral Tibial Tunnel (LTT)
Number of subjects: 20
Study 23162960 — intervention group
Group type: COMPARATOR
Intervention: Classic Anteromedial Tibial Tunnel (MTT)
Number of subjects: 20
Study 21143400 — intervention group
Group type: EXPERIMENTAL
Intervention: CO₂ GAP ≥10
Number of subjects: 412
Study 21143400 — intervention group
Group type: EXPERIMENTAL
Intervention: CO₂ GAP
Number of subjects: 412
Study 21143400 — intervention group
Group type: COMPARATOR
Intervention: Arterial‐alveolar gradient
Number of subjects: 412
Study 17418112 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiar solution (non-optimal solution)
Number of subjects: 0
Study 17418112 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert knowledge
Number of subjects: 0
Study 17418112 — intervention group
Group type: EXPERIMENTAL
Intervention: Einstellung (set) effect paradigm
Number of subjects: 0
Study 15866569 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (600 microg of busereline acetate per day starting in the midluteal phase of the cycle)
Number of subjects: 65
Study 15866569 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist (0.25 mg/d of Cetrorelix starting from day 6 of the cycle)
Number of subjects: 65
Study 12700623 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (increased consumption of fish, fruit, raw and cooked vegetables, and olive oil)
Number of subjects: 11323
Study 12700623 — intervention group
Group type: COMPARATOR
Intervention: Control group (worst dietary score quarter)
Number of subjects: 11323
Study 10896253 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy (HRT)
Number of subjects: 98
Study 10896253 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study 8727840 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived impact of child's chronic illness
Number of subjects: 169
Study 8727840 — intervention group
Group type: EXPERIMENTAL
Intervention: Need to watch for changes in child's condition
Number of subjects: 169
Study 8727840 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of communication or speech problems
Number of subjects: 169
Study 8727840 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of hospitalizations in the previous year
Number of subjects: 169
Study 8727840 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition parameters and service use
Number of subjects: 169
Study 1907128 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy (RT), 45 Gy in 25 fractions (plus a perineal boost of 5 Gy in 2 fractions after abdomino-perineal resection)
Number of subjects: 70
Study 1907128 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (NO RT)
Number of subjects: 70
Study 1907128 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy (RT)
Number of subjects: 70
Study 6340504 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin via the McHenry method
Number of subjects: 317
Study 6340504 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin via the McHenry method
Number of subjects: 317
Study 6340504 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin via the Sawchuk/Zaske method
Number of subjects: 317
Study 6340504 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin via the Sawchuk/Zaske method
Number of subjects: 317
Study 6340504 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated trough serum aminoglycoside concentrations
Number of subjects: 317
Study 6340504 — intervention group
Group type: COMPARATOR
Intervention: Nonelevated trough serum aminoglycoside concentrations
Number of subjects: 317
Study 31210076 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed video
Number of subjects: 133
Study 31210076 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed video
Number of subjects: 133